Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) Program Receives Regulatory Approval

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) traded lower after announcing the approval of its education program, ‘Diarrhea in Foals’ for veterinarians and Veterinary Technicians. Shares of the company fell 6.2% in Tuesday’s trading session to end the day at $0.161 a share.

Jaguar Health Inc. (NASDAQ:JAGX)

Diarrhea in Foals AAVSB Approval

The approval by The American Association of Veterinary State Boards (AAVSB) allows the company to offer 1.50 CE credits to each participating veterinarian or veterinary technician.

“Participation in CE programs helps veterinarians and veterinary technicians remain apprised of current and cutting-edge veterinary care. Helping veterinary professionals expand their clinical knowledge and learn about new technology helps them take better care of their patients,” said equine medical consultant Dr. Siobhan McAuliffe, MVB, DACVIM.

Tuesday’s sell-off capped yet another poor run as the stock continues to register lower lows in the market. The stock has lost more than 70% in market value since the start of the year. Jaguar Health is currently trading in a downtrend and close to its 52-week low of $0.18 a share.

Mytesi Commercialization

Jaguar Health Inc. (NASDAQ:JAGX) is a natural-products pharmaceuticals company focused on developing and commercializing novel gastrointestinal products for human and animal use. The company’s wholly-owned subsidiary develops and commercializes these products for the global marketplace. Mytesi is the company’s lead, FDA-approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS.

Jaguar Health Inc. (NASDAQ:JAGX) subsidiary has launched a ‘Keep your pants on’ campaign as it seeks to raise awareness and engage with people living with HIV and Aids. The campaign seeks to provide an easy way of discussing embarrassing topics such as HIV related diarrhea.

Separately Jaguar Health carried out an underwritten public offering of 21.3 million shares of voting common stock in September. The company expects gross proceeds of $4.25 million after pricing the offering at $0.20 a share.

Jaguar Health Inc. (NASDAQ:JAGX) plans to use net proceeds from the offering for commercialization of its lead product Mytesi and for general corporate purposes as well as working capital.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

This is why Jaguar Health Inc. (NASDAQ:JAGX) Health Dropped 50%

Jaguar Health Inc. (NASDAQ:JAGX)

Jaguar Health Inc. (NASDAQ:JAGX) shares fell over 50% after the natural-products pharmaceutical company announced the pricing of an underwritten public offering of 21.3 million shares. The company expects gross proceeds of $4.25 million from the offering priced at $0.20 a share. The offering should close on or about October 3, 2017.

Investors Reaction

Investors pushed the stock to a new all-time low on the public offering news after the stock broke a key support level. Jaguar Health Inc. (NASDAQ:JAGX) has already recorded a new 52-week low of $0.17 a share as it remains under immense selling pressure.

Jaguar Health Inc. (NASDAQ:JAGX)

The offering appears to have spooked some investors given that it could plunge the company into more debt. The offering could also result in further stock dilution. Jaguar Health Inc. (NASDAQ:JAGX) plans to use proceeds from the offering for general corporate purposes as well as for working capital.

Part of the funds are also to be used for commercialization of the company’s FDA approved human prescription drug Mytesi. The company’s subsidiary Napo Pharmaceuticals has already filed a Chemistry Manufacturing and Controls (CMC) supplement with the U.S Food & Drug Administration (FDA).

Mytesi Commercialization

Mytesi is approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS. The two companies are currently pursuing approval for its use in the treatment of chemotherapy-induced diarrhea for patients undergoing chemotherapy for cancer. The drug is also being tried for the treatment of rare disease indications for infants and children with congenital diarrheal disorders.

“Chronic diarrhea remains a significant complaint of people living with HIV/AIDS, particularly those who are older and have lived the virus in their gut for over 10 years. This is a growing demographic of the HIV community, and Mytesi® is the only antidiarrheal studied in and U.S. FDA-approved for the symptomatic relief of noninfectious diarrhea,” said Pete Riojas, Napo’s national sales director for Mytesi

Jaguar Health Inc. (NASDAQ:JAGX) subsidiary has already expanded its national sale force as it moves to market Mytesi in the U.S. For starters, the company will target sales in New York, Miami, Atlanta and surrounding regions. The drug is currently available in all the 50 states through the Medicaid program. It is also covered by the top 10 commercial insurance plans, which represent more than 245 million American lives.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Jaguar Health Inc (NASDAQ:JAGX) Tightens Control of Mytesi

Jaguar Health Inc (NASDAQ:JAGX)

Jaguar Health Inc (NASDAQ:JAGX) jumped nearly 19% in the last session as the market reacted positively to an announcement about regaining certain rights to the key ingredient in its drug Mytesi.

The stock rose 18.74% to $0.49, thus pushing Jaguar’s market cap up to more than $32.7 million. The gains put Jaguar’s stock gains so far this year at 28.4%. Over the last 12 months, Jaguar shares have dipped to a low of $0.34 and peaked at a high of $1.53.

Jaguar Health Inc (NASDAQ:JAGX) is a pharmaceuticals company focused on the developing and commercializing of innovative gastrointestinal treatments for human and veterinary use.

Jaguar Health Inc (NASDAQ:JAGX)

Regaining rights to Mytesi

On September 25, Jaguar Health Inc (NASDAQ:JAGX) announced that its 100% owned subsidiary Napo Pharmaceuticals has retaken certain rights to crofelemer, the active ingredient in Mytesi, from Glenmark Pharmaceuticals. In a 2005 agreement, Jaguar licensed certain rights tied to development and commercialization of crofelemer to Glenmark, which is based in India. Some of those rights have been returned to Jaguar, bolstering its control of Mytesi – a relief of diarrhea in HIV patients.

The amended agreement with Glenmark returns to Jaguar Health Inc (NASDAQ:JAGX) commercial rights to crofelemer in 141 countries, including India. Glenmark is Napo’s primary manufacturer of crofelemer. Under the 2015 agreement, Glenmark retained development and commercialization rights to crofelemer in India and 140 other countries in the emerging world. The commercial rights to crofelemer in India and those other 140 countries are returning to Jaguar.

Global control of Mytesi

Retaking the rights from Glenmark now gives Jaguar Health Inc (NASDAQ:JAGX) commercial control of Mytesi for all indications globally.

Jaguar Health Inc (NASDAQ:JAGX)’s Mytesi is approved in the U.S. for relief of noninfectious diarrhea in adults with HIV who are on antiretroviral therapy. Jaguar, alongside its Napo subsidiary, is working to expand the treatment label of Mytesi so that it can squeeze even more revenue from the product. For example, Jaguar is pursuing approval of Mytesi for treatment of chemotherapy-induced diarrhea (CID).

In addition to CID, Jaguar Health Inc (NASDAQ:JAGX) is also working to have Mytesi cleared for use in infants and children with short bowel syndrome (SBS). The company is also developing Mytesi for treatment of a wide range of other indications – all of which it now has global commercial control following the retaking of crofelemer rights from Glenmark.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $JAGX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.